| 1 |
NCT02160561 |
Completed |
Feasibility of Upright Bed Position in ARDS Patients |
- Critical Illness
- Acute Respiratory Failure
- Adult Syndrome
|
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Number of participants with change in hemodynamic stability from baseline when placed in upright position
- Number of participants with change in Oxyhemoglobin Saturation from baseline when placed in upright position
- Number of participants with Change in Tidal Volume from baseline when placed in upright position
- Number of participants with change from baseline in Respiratory Rate when placed in upright position
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02160561 |
IRB00023156 |
|
April 2013 |
June 2015 |
June 2015 |
June 10, 2014 |
November 6, 2017 |
|
- Wake Forest Baptist Health, Medical Intensive Care Unit
Winston-Salem, North Carolina, United States
|
| 2 |
NCT00319631 |
Withdrawn |
Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS) |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Weill Medical College of Cornell University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00319631 |
VEGF in ARDS |
|
January 2006 |
January 2017 |
January 2017 |
April 27, 2006 |
January 30, 2017 |
|
- Weill Medical College of Cornell University
New York City, New York, United States
|
| 3 |
NCT00682500 |
Terminated |
Calfactant for Direct Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Drug: Calfactant
- Drug: Room Air (placebo)
|
Interventional |
Phase 3 |
- Pneuma Pharmaceuticals Incorporated
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mortality Rate
- Duration of mechanical ventilation
|
332 |
All |
12 Years to 85 Years (Child, Adult, Senior) |
NCT00682500 |
Pneuma AR-06 |
CARDS |
May 2008 |
December 2010 |
February 2011 |
May 22, 2008 |
July 24, 2012 |
|
- University of Florida
Gainesville, Florida, United States - Florida Hospital and Florida Children's Hospital
Orlando, Florida, United States - Northwestern University-Chicago
Chicago, Illinois, United States - (and 29 more...)
|
| 4 |
NCT00236262 |
Completed |
Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Device: ventilatory strategies with pressure
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single
- Primary Purpose: Treatment
|
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT00236262 |
P040202
PS040202 |
|
October 2005 |
|
September 2006 |
October 12, 2005 |
March 26, 2007 |
|
- HOPITAL HENRI MONDOR Department of Neurosurgery
Creteil, France
|
| 5 |
NCT01195428 |
Withdrawn |
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS) |
- Adult Respiratory Distress Syndrome
- Acute Lung Injury
|
- Drug: Simvastatin
- Drug: Placebo
|
Interventional |
Not Applicable |
- University of Oklahoma
- VA Office of Research and Development
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01195428 |
15377 |
|
October 2010 |
October 2011 |
October 2011 |
September 6, 2010 |
January 7, 2014 |
|
- OU Medical Center
Oklahoma City, Oklahoma, United States - Veterans Affairs Medical Center
Oklahoma City, Oklahoma, United States
|
| 6 |
NCT03236272 |
Not yet recruiting |
Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS) |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Mingdong Hu
- Third Military Medical University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the change of protein biomarkers expression
- the change of microRNA-126(miR-126) expression
- the change of microRNA-146a(miR-146a) expression
- (and 2 more...)
|
376 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03236272 |
TMMUHMD76 |
|
August 1, 2017 |
August 30, 2019 |
December 30, 2019 |
August 1, 2017 |
August 3, 2017 |
|
|
| 7 |
NCT00416260 |
Completed |
Combined High Frequency Oscillation and Tracheal Gas Insufflation for Severe Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Other: High Frequency Oscillation and Tracheal Gas Insufflation
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Physiological variables (i.e. ventilation pressures and oxygenation) during the first 7-10 days following randomization
- Survival to days 28 and 60 post-randomization and to Hospital Discharge
- Ventilator free days
- (and 2 more...)
|
54 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00416260 |
10532-HFO-TGI |
|
July 2006 |
September 2007 |
September 2007 |
December 27, 2006 |
June 24, 2014 |
|
- Evaggelismos General Hospital
Athens, Attica, Greece
|
| 8 |
NCT00465309 |
Completed |
Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS) |
- Adult Respiratory Distress Syndrome
|
- Procedure: protective ventilation with CO2 removal technique
|
Interventional |
Phase 3 |
- University of Turin, Italy
- Regione Piemonte
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pulmonary inflammatory mediator reduction
|
200 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00465309 |
PR60ANMA06 |
|
April 2007 |
|
November 2008 |
April 25, 2007 |
January 12, 2009 |
|
- University of Turin, Department of Anesthesia and Intensive Care Medicine,S. G. Battista Hospital
Turin, Italy - University of Turin, Department of Anesthesia and Intensive Care Medicine
Turin, Italy
|
| 9 |
NCT03111212 |
Not yet recruiting |
Iloprost in Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Drug: Iloprost
- Drug: control
|
Interventional |
Phase 3 |
- University Hospital Tuebingen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
900 |
All |
18 Years and older (Adult, Senior) |
NCT03111212 |
ThIlo |
ThIlo |
June 2018 |
October 2020 |
January 2021 |
April 12, 2017 |
April 27, 2017 |
|
- University Hospital Tuebingen
Tuebingen, Germany
|
| 10 |
NCT02097641 |
Active, not recruiting |
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START) |
- Respiratory Distress Syndrome, Adult
|
- Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- Biological: Plasma-Lyte A
|
Interventional |
Phase 2 |
- Michael A. Matthay
- National Heart, Lung, and Blood Institute (NHLBI)
- Massachusetts General Hospital
- (and 5 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Incidence of pre-specified infusion associated events occurring within 6 hours of study infusion
- Any cardiac arrest or death within 24 hours of study infusion
- Any unexpected severe adverse events in two groups
- (and 3 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02097641 |
UCSF-hMSC-ARDS-P2
1U01HL108713-01 |
START |
March 15, 2014 |
March 9, 2017 |
February 9, 2018 |
March 27, 2014 |
May 3, 2017 |
|
- University of California San Francisco
San Francisco, California, United States - Stanford University
Stanford, California, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 3 more...)
|
| 11 |
NCT01716962 |
Unknown † |
Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Other: Infusion of 6% tetrastarch for a total of 500 ml
|
Observational |
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- increase of cardiac output after volume expansion
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01716962 |
CGMF IRB 100-4473A3 |
|
November 2012 |
July 2014 |
|
October 30, 2012 |
December 3, 2012 |
|
- Chang Gung Memorial Hospital
Taipei, Taiwan
|
| 12 |
NCT02622724 |
Active, not recruiting |
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) |
- Respiratory Distress Syndrome, Adult
|
- Drug: Interferon beta-1a
- Drug: Placebo
|
Interventional |
Phase 3 |
- Faron Pharmaceuticals Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Efficacy Endpoint: Any cause death
- Efficacy Endpoint: Days free of mechanical ventilation
- Evaluation of Safety: Adverse events and all deaths
- (and 17 more...)
|
301 |
All |
18 Years and older (Adult, Senior) |
NCT02622724 |
FPCLI002 |
INTEREST |
December 28, 2015 |
March 2018 |
December 2018 |
December 4, 2015 |
December 20, 2017 |
|
- Erasmus Hospital
Brussels, Belgium - UZ Brussel
Brussels, Belgium - UZ Antwerpen
Edegem, Belgium - (and 68 more...)
|
| 13 |
NCT01807091 |
Recruiting |
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
- Adult Acute Myeloid Leukemia
- Adult Myelodysplastic Syndrome
|
|
Interventional |
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of hospital admission
- TRM rate
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT01807091 |
7910
NCI-2013-00483
P30CA015704 |
|
May 21, 2013 |
October 1, 2018 |
|
March 8, 2013 |
January 5, 2018 |
|
- Bozeman Deaconess Hospital
Bozeman, Montana, United States - Kadlec Clinic Hematology and Oncology
Kennewick, Washington, United States - EvergreenHealth Medical Center
Kirkland, Washington, United States - (and 6 more...)
|
| 14 |
NCT00399581 |
Completed |
Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Procedure: High Frequency Oscillatory Ventilation-Hi
- Procedure: High Frequency Oscillatory Ventilation-Lo
|
Interventional |
Phase 2 |
- Johns Hopkins University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of ventilator free days
- Changes in plasma concentration of IL-6
- Number of intensive care unit free days
- (and 7 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT00399581 |
471
P50HL073994 |
|
November 2006 |
May 2009 |
June 2009 |
November 15, 2006 |
February 27, 2013 |
|
- Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States - Johns Hopkins Hospital
Baltimore, Maryland, United States - University of Maryland Medical Center
Baltimore, Maryland, United States - (and 2 more...)
|
| 15 |
NCT02799940 |
Recruiting |
Abnormalities in Lung Computed Tomography and Physiological Alterations in Patients With Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Hospital Regional Rio Gallegos
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation between the extent of oxygenation and the degree of consolidation (total CO) in the CT scan.
- Correlation between the driving pressure and the total CO as evidenced by CT
- Correlation between the static pressure and the total CO evidenced by CT
- (and 6 more...)
|
29 |
All |
15 Years and older (Child, Adult, Senior) |
NCT02799940 |
MJL001 |
|
August 2016 |
August 2018 |
June 2019 |
June 15, 2016 |
February 23, 2018 |
|
- Hospital Regional Rio Gallegos
Rio Gallegos, Santa Cruz, Argentina
|
| 16 |
NCT02804373 |
Recruiting |
Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome |
|
- Drug: Oxytocin continuous
- Drug: Placebo
- Drug: Placebo continuous
- Drug: Oxytocin
|
Interventional |
Phase 2
Phase 3 |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Behaviour as assessed by score variations in specific questionaries
- Change in eating Behaviour as assessed by score variations in specific questionaries
- Change in eating behaviour as assessed by score variations in hunger visual analogic scale
- (and 8 more...)
|
39 |
All |
18 Years to 50 Years (Adult) |
NCT02804373 |
13 6872 03 |
PRADOTIM |
June 2014 |
July 2016 |
July 2016 |
June 17, 2016 |
June 17, 2016 |
|
- Centre de référence Prader-Willi - Hôpital Purpan
Toulouse, France
|
| 17 |
NCT01256333 |
Completed |
Optimization of Arterial Oxygen Transport by Positive End-expiratory Pressure Variation in Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Rennes University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determinate the Positive End-Expiratory Pressure (PEEP) level achieving the best arterial oxygen transport (TaO2)
- Evolution of pulmonary gas exchanges
- Evolution of respiratory mechanism parameters
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01256333 |
2010-A00942-37
LOC/10-08 |
OPTIPEP |
January 2011 |
|
|
December 8, 2010 |
July 3, 2013 |
|
- Perigueux Hospital
Perigueux, Aquitaine, France - Rennes University Hospital
Rennes, Britanny, France
|
| 18 |
NCT01119872 |
Completed |
Pilot Study of Positive-End Expiratory Pressure in Acute Respiratory Distress Syndrome |
- Respiratory Distress Syndrome, Adult
|
- Other: Positive End-expiratory Pressure (PEEP)
|
Interventional |
Not Applicable |
- Hospital Universitario Principe de Asturias
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Arterial Oxygenation
- Mortality
- Number of ventilator-free days at day 28
- multivariate analysis of mortality
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT01119872 |
UCI-HUPA-1 |
PEEP-HUPA |
January 2003 |
December 2007 |
December 2008 |
May 10, 2010 |
May 10, 2010 |
|
- Critical Care Unit. Universitary Hospital Principe de Asturias
Alcalá de Henares, Madrid, Spain
|
| 19 |
NCT01374022 |
Active, not recruiting |
ART - Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial |
- Respiratory Distress Syndrome, Adult
|
- Other: ART Strategy
- Other: ARDSNet Strategy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival in 28 days
- Lenght of ICU stay
- Lenght of hospital stay
- (and 6 more...)
|
1013 |
All |
18 Years and older (Adult, Senior) |
NCT01374022 |
CAAE - 0025.1.160.000-11 |
ART |
June 2011 |
May 2017 |
October 2017 |
June 15, 2011 |
May 9, 2017 |
|
- Hospital do Coracao
Sao Paulo, SP, Brazil
|
| 20 |
NCT00155779 |
Completed |
ACE Gene Polymorphism and ARDS Outcome |
- Adult Respiratory Distress Syndrome
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Allocation: Random Sample
- Observational Model: Natural History
- Time Perspective: Cross-Sectional
- Time Perspective: Retrospective/Prospective
|
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT00155779 |
9100207816 |
|
December 2003 |
|
December 2004 |
September 12, 2005 |
September 12, 2005 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 21 |
NCT02215811 |
Unknown † |
Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells |
- Acute Respiratory Distress Syndrome, Adult
|
- Biological: Mesenchymal stromal cells
|
Interventional |
Phase 1 |
- Karolinska University Hospital
- Karolinska Institutet
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- In-hospital mortality
- Pulmonary compliance
- Pulmonary tidal volume
- (and 3 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02215811 |
MSC-ARDS |
|
March 2014 |
December 2015 |
|
August 13, 2014 |
August 13, 2014 |
|
- Karolinska University Hospital
Stockholm, Sweden - Uppsala University Hospital
Uppsala, Sweden
|
| 22 |
NCT00883948 |
Completed |
Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study) |
- Respiratory Distress Syndrome, Adult
|
- Behavioral: Minimal (Trophic) Feeding
- Behavioral: Full Feeding
|
Interventional |
Phase 3 |
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of ventilator-free days (VFD)
- Mortality before hospital discharge, with unassisted breathing
- Number of intensive care unit-free days
- (and 7 more...)
|
1000 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00883948 |
651
N01-HR056179, HSN268200536179C |
EDEN |
December 2007 |
March 2011 |
May 2011 |
April 20, 2009 |
April 13, 2016 |
|
- University of San Francisco-Fresno Medical Center
Fresno, California, United States - University of California, Davis Medical Center
Sacramento, California, United States - University of California, San Francisco (UCSF)-Moffitt Hospital
San Francisco, California, United States - (and 36 more...)
|
| 23 |
NCT00609180 |
Terminated |
Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study) |
- Respiratory Distress Syndrome, Adult
|
- Behavioral: Minimal (Trophic) Feeding
- Behavioral: Full Feeding
- Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements
- Dietary Supplement: Placebo
|
Interventional |
Phase 3 |
- National Heart, Lung, and Blood Institute (NHLBI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of ventilator-free days (VFD)
- Mortality before hospital discharge, with unassisted breathing
- Number of intensive care unit-free days
- (and 7 more...)
|
272 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00609180 |
549
N01-HR056179, HSN268200536179C |
EDEN-Omega |
December 2007 |
February 2009 |
April 2009 |
February 6, 2008 |
April 13, 2016 |
|
- University of San Francisco-Fresno Medical Center
Fresno, California, United States - University of California, Davis Medical Center
Sacramento, California, United States - UCSF-Moffitt Hospital
San Francisco, California, United States - (and 38 more...)
|
| 24 |
NCT02895802 |
Active, not recruiting |
Assessing the Feasibility of the Use of Visual Aids in Patient Education in Adults With Down Syndrome (DS) |
|
- Behavioral: Verbal instructions with picture diagram
- Behavioral: Verbal instructions with video of ADSC
- Behavioral: verbal instructions w. video of w/o DS
- Behavioral: verbal instructions w. video w/DS
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Score on handwashing checklist
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02895802 |
6360 |
|
August 2016 |
December 2016 |
October 2018 |
September 12, 2016 |
March 29, 2018 |
|
- Adult Down Syndrome Center / Russell Institute for Research and Innovation
Park Ridge, Illinois, United States
|
| 25 |
NCT01475383 |
Terminated |
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome |
|
- Drug: PF-03654746
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Total Tic Score (Yale Global Tic Severity Scale) from baseline (D0) to end of the 3 wk stable dosing phase (D41)(primary). Average of the 2 assessments of Total Tic Score in 3 wk stable dosing phase is secondary. Score 0-50 (50 = severe)
- Change in Tic Symptom Self Report from baseline to end of 3-wk stable dosing phase (primary); average of 2 assessments of TSSR during 3-wk stable dosing phase is 2ndary. Each symptom is scored 0-3; higher score is worse.
- Change in Premonitory Urge for Tic Scale from baseline to end of 3-wk stable dosing phase (primary); average of 2 assessments of PUTS during 3-wk stable dosing phase is 2ndary. Score 9-36; higher score is worse.
- (and 7 more...)
|
1 |
All |
18 Years to 55 Years (Adult) |
NCT01475383 |
A8801035 |
|
April 2012 |
April 2012 |
April 2012 |
November 21, 2011 |
August 1, 2012 |
|
- Pfizer Investigational Site
Manhasset, New York, United States
|
| 26 |
NCT01303133 |
Active, not recruiting |
Natural History of Amyloid Deposition in Adults With Down Syndrome |
|
|
Observational |
|
- University of Pittsburgh
- National Institute on Aging (NIA)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
|
81 |
All |
30 Years and older (Adult, Senior) |
NCT01303133 |
PRO09080266
2R01AG031110-03A1 |
|
August 2009 |
March 31, 2018 |
March 31, 2018 |
February 24, 2011 |
August 1, 2017 |
|
- University of Pittsburgh and University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States - Waisman Center at the University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 27 |
NCT02134080 |
Suspended |
FAAH Inhibitor Trial for Adults With Tourette Syndrome |
|
- Drug: PF-04457845
- Drug: Placebo
|
Interventional |
Phase 2 |
- Yale University
- Tourette Association of America
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in Tic Severity
- Improvement of Premonitory Urges
- Improvement in Obsessive Compulsive Disorder (OCD) Severity
- (and 7 more...)
|
10 |
All |
18 Years to 60 Years (Adult) |
NCT02134080 |
1403013669 |
|
May 2014 |
May 2017 |
December 2017 |
May 8, 2014 |
March 22, 2016 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States
|
| 28 |
NCT01719523 |
Completed |
Open-Trial of EPI-743 for Adults With Tourette Syndrome |
|
|
Interventional |
Phase 1 |
- Yale University
- Rembrandt Foundation
- Edison Pharmaceuticals Inc
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Yale Global Tic Severity Scale
- Premonitory Urge for Tics Scale
- Yale-Brown Obsessive Compulsive Scale
- (and 5 more...)
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT01719523 |
120100953972412 |
|
October 2012 |
October 2013 |
October 2013 |
November 1, 2012 |
March 5, 2014 |
|
- Yale Child Study Center
New Haven, Connecticut, United States
|
| 29 |
NCT03332537 |
Recruiting |
Precision Pain Self-Management in Young Adults With Irritable Bowel Syndrome |
|
- Behavioral: Personalized IBS Pain SM
|
Interventional |
Not Applicable |
- University of Connecticut
- National Institute of Nursing Research (NINR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Change in pain sensitivity
- Change in gut microbiome
- Genetic variations (Pain-susceptibility SNPs genotyping)
|
80 |
All |
18 Years to 29 Years (Adult) |
NCT03332537 |
H16-152
1P20NR016605-01 |
IBS-SM |
October 1, 2016 |
April 30, 2018 |
April 30, 2018 |
November 6, 2017 |
November 6, 2017 |
|
- UConn Health Center
Farmington, Connecticut, United States - University of Connecticut
Storrs, Connecticut, United States
|
| 30 |
NCT01839864 |
Withdrawn |
Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial |
|
- Behavioral: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
|
Interventional |
Not Applicable |
- Family Medicine Residency of Idaho
- Mountain States Group
- Saint Alphonsus Medical Group
- Quantified, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Patient Activation Measure from baseline to six months and six months to one year
- Changes in patient attitudes about providers and carefrom baseline to six months and six months to one year
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01839864 |
FMRI Promotora Trial |
FMRIMetSynd |
September 2013 |
June 2016 |
August 2016 |
April 25, 2013 |
February 14, 2017 |
|
- Saint Alphonsus Medical Group Caldwell Clinic
Caldwell, Idaho, United States - Saint Lukes Clinic Jerome
Jerome, Idaho, United States - St Alphonsus Medical Group Nampa Clinic
Nampa, Idaho, United States
|
| 31 |
NCT01167621 |
Completed |
Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Centre Hospitalier Universitaire de la Réunion
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Indexed Extra Vascular Lung Water (EVLWI) changes under HFO ventilation
- Hemodynamics changes under HFO ventilation
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01167621 |
2010/CHR/01 |
|
September 2010 |
September 2012 |
September 2012 |
July 22, 2010 |
July 29, 2015 |
|
- Réanimation polyvalente, University Hospital Reunion Island - Felix Guyon Site
Saint Denis de La Réunion, France
|
| 32 |
NCT00896272 |
Completed |
Adaptation Among Adolescents and Adults With Klinefelter Syndrome |
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Retrospective
|
- Adaptation to Klinefelter. The primary research question is to answer how adolescents and adults adapt to Klinefelter syndrome.
- Open ended questions will also assess most difficult and best aspects of living with the condition. Follow-up research will be aimed at opportunities for enhancing adaptation.
|
302 |
Male |
14 Years to 80 Years (Child, Adult, Senior) |
NCT00896272 |
999909142
09-HG-N142 |
|
May 5, 2009 |
|
January 13, 2015 |
May 11, 2009 |
April 17, 2018 |
|
- National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 33 |
NCT02664090 |
Completed |
Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in ARDS Patients |
- Respiratory Distress Syndrome, Adult
|
|
Observational |
|
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To measure pattern of changes in cardiac index (L/min/m2) from baseline (pre-prone position) to during prone position.
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT02664090 |
2015-139-DM-88 |
|
January 20, 2016 |
January 18, 2017 |
January 18, 2017 |
January 26, 2016 |
February 1, 2017 |
|
- Department of Critical Care Medicine
Lucknow, Uttar Pradesh, India
|
| 34 |
NCT00951730 |
Completed |
Evaluation of a Simplified Method for Diagnosis of Sleep Apnea in Children and Adults With Down Syndrome |
|
|
Observational |
|
- Centre Hospitalier Universitaire de Saint Etienne
- Ministry of Health, France
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Apnea / hypopnea events index determined by reading the complete polysomnography (review reference) and apnea / hypopnoea events index determined by the simplified five parameters of the polysomnography
- Questionnaire on sleep
- Psychometric tests
|
97 |
All |
2 Years and older (Child, Adult, Senior) |
NCT00951730 |
0808017
2008-A01273-52 |
SAOS/T21 |
February 2010 |
February 2015 |
February 2015 |
August 4, 2009 |
July 7, 2015 |
|
- CHU de Grenoble
Grenoble, France - Hospices Civiles de lyon
Lyon, France - CHU de Saint-Etienne
Saint-etienne, France
|
| 35 |
NCT01868477 |
Completed |
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. |
- Adult Patients With Low Risk Myelodysplastic Syndrome
- Adult Patients With Int 1-risk Myelodysplastic Syndrome
|
- Drug: Erythropoietin alpha
- Drug: Deferasirox
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in hemoglobin levels
- Change in hemoglobin, platelets and neutrophil levels
- Time to erythroid response
- (and 6 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01868477 |
CICL670A2421 |
|
January 28, 2014 |
March 22, 2017 |
March 22, 2017 |
June 4, 2013 |
February 21, 2018 |
|
- Novartis Investigative Site
Oran, Algeria - Novartis Investigative Site
Sidi Bel abbes, Algeria - Novartis Investigative Site
Caba, Buenos Aires, Argentina - (and 27 more...)
|
| 36 |
NCT01854060 |
Completed |
Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of Young Adults. |
|
|
Observational |
|
- Medical Corps, Israel Defense Force
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Incidence of clinical diagnosis of irritable bowel syndrome
- predictive factors for the clinical diagnosis of irritable bowel syndrome
|
440822 |
All |
18 Years to 39 Years (Adult) |
NCT01854060 |
IDF-1083-2011 |
|
January 2013 |
May 2013 |
May 2013 |
May 15, 2013 |
May 15, 2013 |
|
- Israel Defence Forces, Medical Corps
Ramat Gan, Israel
|
| 37 |
NCT02996305 |
Recruiting |
A Study in Adults and Adolescents With Angelman Syndrome |
|
- Drug: OV101 Regimen 1
- Drug: OV101 regimen 2
- Other: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of adverse events in placebo and active treatment groups
- Exploratory efficacy measurement for motor function
- Exploratory efficacy measurement for sleep
- (and 3 more...)
|
75 |
All |
13 Years to 49 Years (Child, Adult) |
NCT02996305 |
OV101-15-001 |
|
January 2016 |
October 2018 |
November 2018 |
December 19, 2016 |
November 30, 2017 |
|
- Ovid Therapeutics Investigative Site
Phoenix, Arizona, United States - Ovid Therapeutics Investigative Site
San Diego, California, United States - Ovid Therapeutics Investigative Site
Gainesville, Florida, United States - (and 10 more...)
|
| 38 |
NCT02126995 |
Completed |
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome |
|
- Drug: MG01CI extended-release tablet
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Evaluation of efficacy of MG01CI by Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale (ADHD RS-IV)
- Evaluation of efficacy of MG01C as measured by total score on the ADHD RS-IV.
|
62 |
All |
15 Years to 55 Years (Child, Adult) |
NCT02126995 |
AL014 |
|
June 2014 |
June 2015 |
June 2015 |
April 30, 2014 |
July 6, 2016 |
|
- Southwest Autism Research & Resource Center
Phoenix,, Arizona, United States - University of California Davis Pediatrics
Sacramento,, California, United States - Children's Hospital Colorado
Aurora,, Colorado, United States - (and 9 more...)
|
| 39 |
NCT02024789 |
Completed |
A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) |
|
- Drug: Placebo
- Drug: RG1662
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests
- Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores
- Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale
- (and 5 more...)
|
173 |
All |
12 Years to 30 Years (Child, Adult) |
NCT02024789 |
BP27832
2013-001263-23 |
|
May 5, 2014 |
May 4, 2016 |
May 4, 2016 |
December 31, 2013 |
October 25, 2017 |
|
- Univ of CA San Diego; Neurosciences Comp.Alzheimer's
La Jolla, California, United States - University of California DAVIS Medical Center; M.I.N.D. Institute, Section of Developmental Behavior
Sacramento, California, United States - Emory University School of Medicine; Department of Human Genetics & Pediatrics
Decatur, Georgia, United States - (and 34 more...)
|
| 40 |
NCT01253629 |
Completed |
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome |
|
- Drug: AFQ056
- Drug: Placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in behavioral symptoms of Fragile X Syndrome using the Aberrant Behavior Checklist - Community (ABC-C) Total score in Stratum I
- Change from baseline in behavioral symptoms of Fragile X Syndrome (FXS) using the ABC-C Total score in Stratum II
- Global improvement of symptoms in Fragile X using the Clinical Global Impression-Improvement (CGI-I) scale
- (and 3 more...)
|
175 |
All |
18 Years to 45 Years (Adult) |
NCT01253629 |
CAFQ056A2212
2009-013667-19 |
|
November 2010 |
August 2013 |
August 2013 |
December 3, 2010 |
April 25, 2016 |
|
- Novartis Investigative Site
Phoenix, Arizona, United States - Novartis Investigative Site
Sacramento, California, United States - Novartis Investigative Site
Decatur, Georgia, United States - (and 28 more...)
|
| 41 |
NCT03355469 |
Recruiting |
Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome |
|
- Combination Product: LoEx+Metformin
- Combination Product: HiEx+Metformin
- Combination Product: LoEx+Placebo
- Combination Product: HiEx+Placebo
|
Interventional |
Phase 4 |
- University of Virginia
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in Flow Mediated Dilation of brachial artery
- Change in Metabolic Insulin Sensitivity by the Euglycemic Clamp
- Change in Post Ischemic Flow Velocity in brachial artery
- (and 4 more...)
|
80 |
All |
40 Years to 70 Years (Adult, Senior) |
NCT03355469 |
19364
1R01HL130296-01A1 |
|
August 7, 2017 |
June 30, 2021 |
January 31, 2022 |
November 28, 2017 |
November 28, 2017 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
| 42 |
NCT03326037 |
Recruiting |
Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East |
|
- Genetic: Genotyping of the NPHS2 variant rs61747728
|
Observational |
|
- AHMED ABDULQADER HAMMOUDA ABOU SHALL
- Kuwait University
- Assiut University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of participants achieving NPHS2 gene mutations (frequency of p.R229Q polymorphic site) in patients with steroid-resistant nephrotic syndrome in comparison with steroid - sensitive nephrotic syndrome
|
150 |
All |
2 Years to 50 Years (Child, Adult) |
NCT03326037 |
MG03/15 |
|
October 2016 |
October 2018 |
August 2019 |
October 30, 2017 |
October 30, 2017 |
|
- Faculty of Medicine-Pathology Department
Ḩawallī, Kuwait
|
| 43 |
NCT00640757 |
Completed |
Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome |
|
- Dietary Supplement: Methionine deficient diet
- Dietary Supplement: Methionine sufficient diet
|
Interventional |
Phase 2 |
- Pennington Biomedical Research Center
- Orentreich Foundation for the Advancement of Science, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Weight loss
- Improve glucose metabolism
|
56 |
All |
21 Years to 60 Years (Adult) |
NCT00640757 |
PBRC 26009 |
|
July 2006 |
December 2008 |
December 2008 |
March 21, 2008 |
December 18, 2015 |
|
|
| 44 |
NCT02950987 |
Recruiting |
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes |
|
|
Interventional |
Early Phase 1 |
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Return of pediatric and adult patients with Li Fraumeni Syndrome year-after-year for 2 annual scans.
- Return of pediatric and adult patients with other cancer predisposition syndromes year-after-year for 2 annual scans.
- Detection of prevalent and incident cancers on WB-MRI in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.
- Detection of prevalent and incident cancers on additional screening studies in pediatric and adult patients with Li Fraumeni and other inherited cancer predisposition syndromes.
|
150 |
All |
Child, Adult, Senior |
NCT02950987 |
11-200 |
|
March 2012 |
September 2019 |
September 2021 |
November 1, 2016 |
November 1, 2016 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 45 |
NCT03100942 |
Recruiting |
Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome |
|
- Drug: Filgotinib
- Drug: GS-9876
- Drug: Tirabrutinib
- (and 3 more...)
|
Interventional |
Phase 2 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline
- Change from Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12
- Change from Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12
- (and 2 more...)
|
140 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03100942 |
GS-US-445-4189
2016-003558-34 |
|
May 1, 2017 |
August 2018 |
May 2019 |
April 4, 2017 |
April 3, 2018 |
|
- AARR Arizona Arthritis & Rheumatology Research
Mesa, Arizona, United States - AARR Arizona Arthritis & Rheumatology Research
Phoenix, Arizona, United States - Medvin Clinical Research
Covina, California, United States - (and 59 more...)
|
| 46 |
NCT01282268 |
Completed |
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome |
|
- Drug: arbaclofen
- Drug: placebo
|
Interventional |
Phase 3 |
- Seaside Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Aberrant Behavior Checklist - FXS Social Avoidance Subscale
|
125 |
All |
12 Years to 50 Years (Child, Adult) |
NCT01282268 |
209FX301 |
Harbor-A |
May 2011 |
December 2012 |
|
January 24, 2011 |
July 31, 2013 |
|
- Southwest Autism Research & Resource Center
Phoenix, Arizona, United States - Miller Children's Hospital Research Administration
Long Beach, California, United States - University of California-Davis, M.I.N.D. Institute
Sacramento, California, United States - (and 21 more...)
|
| 47 |
NCT02804945 |
Recruiting |
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies |
- Blood And Marrow Transplantation
- Adult Respiratory Distress Syndrome
|
- Biological: Mesenchymal Stem Cells (MSCs)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Katz Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)
- Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)
- Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02804945 |
2015-0327
NCI-2016-01184 |
|
February 24, 2017 |
February 2020 |
February 2021 |
June 17, 2016 |
March 8, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 48 |
NCT03140813 |
Recruiting |
An Initial Study of AZD7325 in Adults With Fragile X Syndrome |
|
- Drug: AZD7325 (High-Dose)
- Drug: AZD7325 (Low-Dose)
- Drug: Placebo oral capsule
|
Interventional |
Phase 1 |
- Children's Hospital Medical Center, Cincinnati
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Amyloid Precursor Protein (APP)
- Change in the Social Withdrawal subscale score of the Aberrant Behavior Checklist (ABC)
- Change in the Pediatric Anxiety Rating Scale (PARS)
|
15 |
All |
18 Years to 50 Years (Adult) |
NCT03140813 |
CIN001 - AZD7325 in FXS |
|
January 16, 2018 |
May 2018 |
July 2018 |
May 4, 2017 |
March 6, 2018 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 49 |
NCT02594215 |
Enrolling by invitation |
Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome |
|
|
Interventional |
Phase 1 |
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tissue drug levels
- Tissue phospho-AKT level
- Tolerability and side effects
|
6 |
All |
6 Years to 65 Years (Child, Adult) |
NCT02594215 |
160014
16-HG-0014 |
|
October 31, 2015 |
December 31, 2019 |
December 31, 2019 |
November 3, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 50 |
NCT03236571 |
Not yet recruiting |
Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome. |
|
- Device: Rehabilitation program
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Measurement of the maximum endurance capacities.
- Fatigability with effort and quality of life.
- Muscular force.
- (and 5 more...)
|
30 |
All |
7 Years to 25 Years (Child, Adult) |
NCT03236571 |
RC31/17/0257 |
Marfanpower |
May 2018 |
February 2021 |
February 2021 |
August 2, 2017 |
February 6, 2018 |
|
- CHU de Toulouse
Toulouse, Midi-Pyrénées, France
|
Create an RSS feed from your search for:
Download the search results for: